MedTrace Logo

Curcumin in Patients With Mild to Moderate Alzheimer's Disease

NCT00099710 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2009-12-03

No results posted yet for this study

Summary

The purpose of this study is to examine the safety and tolerability of curcumin, and to determine its effect on patients with mild to moderate Alzheimer's Disease (AD).

Conditions

Interventions

DIETARY_SUPPLEMENT

Curcumin C3 Complex

Sponsors & Collaborators

  • Institute for the Study of Aging (ISOA)

    collaborator OTHER

  • John Douglas French Foundation

    lead OTHER

Principal Investigators

  • John Ringman, MD · University of California, Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-07-31
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00099710 on ClinicalTrials.gov